C-XZWCAtropos Therapeutics
senescence modulation, phenotypic screening, ATRX
modulatingsmall molecule
Loading
Загрузка раздела...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-XZWC
C-XZWCC-XZWCsenescence modulation, phenotypic screening, ATRX
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Atropos Therapeutics senescence modulation, phenotypic screening, ATRX
Atropos Therapeutics aims to treat aging-related diseases and cancer and improve healthspan with approved novel senescence-targeting drugs. Its FATES platform is a cell-based phenotypic screening platform based on detecting de novo ATRX foci. The company describes applications in aging through senosuppressors and oncology through senostimulators.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Atropos Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (4 programs at exploratory).…
Source: Deterministic